At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- PF-08046876 (drug), Pembrolizumab (combination product), Cisplatin (combination product), Carboplatin (combination product)
- How long the study runs
- Study runs about 47 months (dates as stated)
- About the drug or intervention
- PF-08046876 — drug: Intravenous administration · Pembrolizumab — combination product: Intravenous administration · Cisplatin — combination product: Intravenous administration · Carboplatin — combination product: Intravenous administration
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 540
- Started
- 2025-08-20
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for advanced/metastatic solid tumors
- • Phase1 - 540 participants
- • The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with advanced/metastatic solid tumors
Where?
- • London - Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London
- • Manchester - The Christie NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules. In the second part of the study, groups of people will receive the study drug in dosing regimens deemed to be safe in Part 1. In the third part of the study, people will receive the study drug together with other anti-cancer medicines.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
- How fit you need to be: ECOG 0 or better
Treatment history
Treatments you must have had:
- ✓ requirements vary by combination therapy group
- ✓ pre-treatment tumor tissue as medically feasible
What the study is looking for
- ✓18 years of age or older
- ✓Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas
- ✓cancer that can be measured on scans
- ✓ECOG Performance status 0-1
- ✓Part 1: progression or relapse following standard treatments
Who cannot take part
- ✗Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab...
- ✗Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion
- ✗lung disease meeting protocol exclusion
- ✗Other unacceptable abnormalities as defined by protocol
- ✗Part 3: Meet contraindications of combination products per protocol and/or local labels
See the full criteria
Where Is This Study? (2 UK sites)
Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London
London EC1A 7BE, United Kingdom
The Christie NHS Foundation Trust
Manchester M20 4BX, United Kingdom
How to Get in Touch
Pfizer CT.gov Call Center
Sponsor contactCONTACT